PT-141 vs Semax

Side-by-side comparison of PT-141, Semax — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute PT-141 PT-141 (Bremelanotide) Recovery Semax Semax (Heptapeptide ACTH Analogue) Cognitive
Basics
Molecular type Melanocortin Receptor AgonistACTH-Derived Neuropeptide
Amino acids 77
Molecular weight 1,025.2 Da813.9 Da
Half-life ~2.7 hours~minutes (nasal); longer CNS retention
Route(s) Subcutaneous auto-injectorIntranasal, Subcutaneous
Mechanism & Research
Primary mechanism PT-141 activates melanocortin receptors in the central nervous system — particularly MC3R and MC4R in the hypothalamus and limbic regions. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally through va… Semax's primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) — a neurotrophin critical for neuronal survival, synaptic plasticity, and neurogenesis. In animal models, Semax increases BDNF m…
Research status FDA Approved (Vyleesi) Research Compound
Evidence summary PT-141 (Bremelanotide) was FDA-approved in 2019 based on two Phase 3 trials in premenopausal women with HSDD. Research in men demonstrates pro-erectile effects and is ongoing. Semax has been investigated in Russian clinical research since the 1980s. It has been approved in Russia as a drug for stroke, TBI, and cognitive decline. Western research interest has grown, but large RCTs meeting curre…
Protocol & Dosing
Typical dose 1.75 mg (FDA-approved dose)200–600 mcg/day (intranasal)
Frequency As needed (max 1x per 24 hours)1–2x daily
Duration As needed2–4 weeks cycles
Timing 45 minutes before anticipated sexual activityMorning (or morning + midday); avoid evening to prevent sleep disruption
Safety
Common side effects
  • Nausea (40%)
  • Flushing (20%)
  • Headache (11%)
  • Injection site bruising
  • Nasal irritation
  • Mild stimulation/anxiety (dose-dependent)
  • Headache (initial)
  • Temporary appetite change
Contraindications
  • Uncontrolled hypertension
  • Known cardiovascular disease
  • Use of PDE5 inhibitors (synergistic BP drop)
  • Active psychiatric conditions (bipolar, schizophrenia)
  • Epilepsy/seizure disorders
  • Pregnancy
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides KPV, Semax Selank, Dihexa, P21
Full profile Read full PT-141 profile → Read full Semax profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.